DALLAS, Jan. 13, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring pharmaceutical company MAP Pharmaceuticals Inc. (Nasdaq:MAPP). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/MAPP
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
MAP Pharmaceuticals Inc. (MAPP) is engaged in the development and commercialization of drug therapies focused on medical conditions and diseases not adequately addressed in the marketplace. The Company's lead drug candidate Levadex inhalant is presently in phase III of Food and Drug Administration clinical trials for the treatment of migraine headaches.
In the report, the analyst notes:
"The Company's lead drug candidate, Levadex, is a proprietary orally inhaled version of dihydroergotamine, which is formulated to treat patients suffering from migraine headaches. The competitive advantage of the delivery system is designed to provide pain relief within 30 minutes and treat patients resistant to triptans, a class of drug typically used as a front line treatment regime. The Company estimates that approximately 30 million persons suffer from varying levels, duration and frequency of migraine headaches.
"On January 11, 2010, the Company announced that Levadex will not need to undergo a second pivotal efficacy study as a part of its new drug application (NDA) submission with the FDA. The FDA informed the Company that phase III FREEDOM-301 clinical study, concluded in May 2009, will be adequate and that no further pivotal efficacy study for Levadex is required by the Administration. The Company said that it anticipated a second pivotal efficacy study to begin in the first quarter of 2010."
To read the entire report visit: http://www.beaconequity.com/i/MAPP
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.